Use of clinical investigation data from outside the United States

21 U.S. Code § 360bbb-8b. Use of clinical investigation data from outside the United States

(a) In general
In determining whether to approve, license, or clear a drug, biological product, or device pursuant to an application submitted under this subchapter, the Secretary shall accept data from clinical investigations conducted outside of the United States, including the European Union, if the applicant demonstrates that such data are adequate under applicable standards to support approval, licensure, or clearance of the drug, biological product, or device in the United States.
This document is only available to subscribers. Please log in or purchase access.